[go: up one dir, main page]

NO892447D0 - Fremgangsmaate ved fremstilling av benzofuranderivater. - Google Patents

Fremgangsmaate ved fremstilling av benzofuranderivater.

Info

Publication number
NO892447D0
NO892447D0 NO892447A NO892447A NO892447D0 NO 892447 D0 NO892447 D0 NO 892447D0 NO 892447 A NO892447 A NO 892447A NO 892447 A NO892447 A NO 892447A NO 892447 D0 NO892447 D0 NO 892447D0
Authority
NO
Norway
Prior art keywords
benzofurand
derivatives
preparing
procedure
well
Prior art date
Application number
NO892447A
Other languages
English (en)
Other versions
NO172892C (no
NO892447L (no
NO172892B (no
Inventor
Klaus Peter Boegesoe
Jens Perregaard
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10638616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO892447(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO892447D0 publication Critical patent/NO892447D0/no
Publication of NO892447L publication Critical patent/NO892447L/no
Publication of NO172892B publication Critical patent/NO172892B/no
Publication of NO172892C publication Critical patent/NO172892C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Silicon Compounds (AREA)
NO892447A 1988-06-14 1989-06-13 Fremgangsmaate ved fremstilling av benzofuranderivater NO172892C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888814057A GB8814057D0 (en) 1988-06-14 1988-06-14 New enantiomers & their isolation

Publications (4)

Publication Number Publication Date
NO892447D0 true NO892447D0 (no) 1989-06-13
NO892447L NO892447L (no) 1989-12-15
NO172892B NO172892B (no) 1993-06-14
NO172892C NO172892C (no) 1993-09-22

Family

ID=10638616

Family Applications (2)

Application Number Title Priority Date Filing Date
NO892447A NO172892C (no) 1988-06-14 1989-06-13 Fremgangsmaate ved fremstilling av benzofuranderivater
NO2002014C NO2002014I2 (no) 1988-06-14 2002-11-26 (+)-1-(3-dimetylaminopropyl)1-(4'-fluorfenyl)-1,3 -dihydro-isobenzofuran-5-karbonitril

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2002014C NO2002014I2 (no) 1988-06-14 2002-11-26 (+)-1-(3-dimetylaminopropyl)1-(4'-fluorfenyl)-1,3 -dihydro-isobenzofuran-5-karbonitril

Country Status (24)

Country Link
US (2) US4943590A (no)
EP (1) EP0347066B1 (no)
JP (2) JP3044253B2 (no)
AT (1) ATE119896T1 (no)
AU (1) AU623144B2 (no)
CA (2) CA1339452C (no)
CY (2) CY2081B1 (no)
DE (2) DE68921672T2 (no)
DK (2) DK259989A (no)
ES (1) ES2068891T4 (no)
FI (4) FI98627C (no)
GB (1) GB8814057D0 (no)
GR (1) GR3015889T3 (no)
HK (1) HK139596A (no)
HU (1) HU211460A9 (no)
IE (1) IE65734B1 (no)
IL (1) IL90465A (no)
LU (1) LU90999I2 (no)
MX (1) MX9203346A (no)
NL (1) NL300155I2 (no)
NO (2) NO172892C (no)
NZ (1) NZ229426A (no)
PT (1) PT90845B (no)
ZA (1) ZA894476B (no)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5322851A (en) * 1990-07-02 1994-06-21 H. Lundbeck A/S Indole derivatives
US5665270A (en) * 1991-05-20 1997-09-09 Chisso Corporation Optically active trifluorolactic acid derivative and liquid crystal composition
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
DE4439836C1 (de) * 1994-11-08 1996-06-05 Hoechst Ag cis-4-(2,2,3,3-Tetrafluorpropoxy)-zimtsäurenitril und trans-4-(2,2,3,3-Tetrafluorpropoxy)- zimtsäurenitril und ein Verfahren zu ihrer Herstellung
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
NZ510858A (en) * 1998-10-20 2003-11-28 H Method for the preparation of citalopram
TR200101796T2 (tr) 1998-12-23 2001-11-21 H. Lundbeck A/S 5-Siyanofitalitin preparasyonuna yönelik metot
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
AU759716B2 (en) * 1999-04-14 2003-04-17 H. Lundbeck A/S Method for the preparation of citalopram
US6245782B1 (en) 1999-05-17 2001-06-12 Heartdrug Research L.L.C. Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors
ITMI991579A1 (it) 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6403657B1 (en) 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
DE69920526T2 (de) * 1999-10-25 2006-02-23 H. Lundbeck A/S Verfahren zur herstellung von citalopram
EP1228056B1 (en) * 1999-10-25 2004-09-22 H. Lundbeck A/S Method for the preparation of citalopram
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
PT1246812E (pt) * 1999-12-28 2004-08-31 Lundbeck & Co As H Metodo para a preparacao de citalopram
ES2206177T3 (es) * 2000-01-14 2004-05-16 H. Lundbeck A/S Metodo para la preparacion de 5-cianoftalida.
FR2805812A1 (fr) 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
IL151490A0 (en) * 2000-03-13 2003-04-10 Lundbeck & Co As H Method for the preparation of citalopram
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
WO2001068629A1 (en) * 2000-03-13 2001-09-20 H. Lundbeck A/S Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
DE60101786T2 (de) 2000-03-14 2004-07-15 H. Lundbeck A/S, Valby Verfahren zur herstellung von citalopram
PL360115A1 (en) * 2000-03-16 2004-09-06 H.Lundbeck A/S Method for the preparation of 5-cyano-1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
EA008373B1 (ru) * 2000-07-07 2007-04-27 Х. Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с посттравматическим стрессом
EA008372B1 (ru) * 2000-07-07 2007-04-27 Х.Лундбекк А/С Применение эсциталопрама для лечения расстройства, связанного с социальной тревогой
NZ524252A (en) * 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
CA2353693C (en) * 2000-08-10 2003-07-22 H. Lundbeck A/S Pharmaceutical composition containing citalopram
IL144816A (en) 2000-08-18 2005-09-25 Lundbeck & Co As H Method for the preparation of citalopram
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
PL353369A1 (en) * 2000-12-28 2003-11-17 H.Lundbeck A/S Process for the preparation of pure citalopram
WO2002060886A1 (en) * 2001-01-30 2002-08-08 Orion Corporation, Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
MEP5908A (xx) * 2001-05-01 2010-02-10 Lundbeck & Co As H Upotreba enantiomerno čistog escitaloprama
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034612A1 (es) * 2001-06-25 2004-03-03 Lundbeck & Co As H Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
DK1522539T3 (da) * 2001-07-31 2007-05-07 Lundbeck & Co As H Krystallinsk komposition indeholdende excitalopram
ES2234797T3 (es) * 2001-08-02 2005-07-01 Infosint Sa Procedimiento para la preparacion de citalopram partiendo de 5-formilftalida.
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
US7148364B2 (en) * 2002-01-07 2006-12-12 Sun Pharmaceutical Industries Process for the preparation of 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofuran carbonitrile
WO2003064617A2 (en) * 2002-01-30 2003-08-07 Montana State University Pestalotiopsis microsporia isolates and compounds derived therefrom
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
PE20040991A1 (es) * 2002-08-12 2004-12-27 Lundbeck & Co As H Separacion de intermediarios para la preparacion de escitalopram
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
UA84859C2 (ru) * 2002-12-23 2008-12-10 Х. Луннбек А/С Способ получения свободной основы и/или кислотно-аддитивной соли рацемического циталопрамдиола и/или свободной основы и/или кислотно-аддитивной соли r- или s-циталопрамдиола
CA2511143C (en) 2002-12-23 2011-06-28 H. Lundbeck A/S Preparation of racemic and/or s- or r-citalopram diols and their use for the preparation racemic and/or s- or r-citalopram
BR0317623A (pt) * 2002-12-23 2005-11-29 Lundbeck & Co As H Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
CA2519629A1 (en) * 2003-03-21 2004-09-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
AU2003223105A1 (en) * 2003-03-24 2004-10-18 Hetero Drugs Limited Novel crystalline forms of (s)-citalopram oxalate
EP1486492A3 (en) 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
CA2537402C (en) 2003-09-12 2009-05-05 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors
ES2228274B1 (es) * 2003-09-24 2006-06-01 Astur Pharma, S.A. Sintesis quimioenzimatica de (+)-citalopram y (-)-citalopram.
ES2240931T3 (es) * 2003-10-28 2005-10-16 Adorkem Technology Spa Procedimiento para la preparacion de citalopram.
US20050101666A1 (en) * 2003-11-07 2005-05-12 H. Lundbeck A/S Method of treating premenstrual dysphoric disorder with escitalopram
WO2005047274A1 (en) * 2003-11-12 2005-05-26 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
US20050107466A1 (en) * 2003-11-17 2005-05-19 H. Lundbeck A/S Method of treating or reducing suicidal thoughts with escitalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
AU2003282383A1 (en) * 2003-11-20 2005-06-08 Natco Pharma Limited A process for the preparation of high purity escitalopram
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
CA2558198A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
ITMI20040717A1 (it) 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
EP1737473A4 (en) * 2004-04-19 2009-08-26 Noven Therapeutics Llc COMBINATIONS OF LITHIUM AND USES THEREOF
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
EP2141156A1 (en) * 2004-08-23 2010-01-06 Sun Pharma Global FZE Process for Preparation of Citalopram and Enantiomers
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
WO2006025071A1 (en) * 2004-09-02 2006-03-09 Natco Pharma Limited A process for the preparation of escitalopram
ITMI20041872A1 (it) 2004-10-01 2005-01-01 Adorkem Technology Spa Processo per la preparazione di citalopram e di scitalopram
EP1877394A1 (en) * 2005-04-04 2008-01-16 Jubilant Organosys Limited Process for the preparation of escitalopram or its acid addition salts
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
AU2006239937A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
TW200719886A (en) * 2005-04-22 2007-06-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
CA2605554A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
CA2604916A1 (en) 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
ITTO20050301A1 (it) * 2005-05-05 2006-11-06 Errekappa Euroterapici Spa Formulazioni liquide orali contenenti citalopram
US20110196032A1 (en) * 2005-05-20 2011-08-11 Ashish Gogia Pharmaceutical Dosage Form of an Antidepressant
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI347942B (en) 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EP1987016A1 (en) * 2005-07-27 2008-11-05 Aurobindo Pharma Limited An improved process for the preparation of escitalopram
AU2006308635A1 (en) * 2005-10-14 2007-05-10 H. Lundbeck A/S Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
AU2006304889A1 (en) * 2005-10-14 2007-04-26 H. Lundbeck A/S Stable pharmaceutical formulations containing escitalopram and bupropion
WO2007054105A2 (en) * 2005-11-14 2007-05-18 H. Lundbeck A/S Method for the preparation of escitalopram
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
RU2463039C2 (ru) * 2006-10-20 2012-10-10 Рациофарм Гмбх Эсциталопрам и твердая фармацевтическая композиция, его содержащая
JP5404048B2 (ja) 2006-10-27 2014-01-29 久光製薬株式会社 貼付剤
US20080153881A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153808A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2 receptor pan agonist and serotonin-norepinephrine reuptake inhibitor compositions for treating chronic pain
US20080153880A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and acid reducer compositions for treating gastrointestinal motility disorders
US20080153874A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and anticonvulsant compositions for treating chronic pain
US20080153825A1 (en) * 2006-12-22 2008-06-26 Allergan Inc. Alpha-2b receptor agonist and 5ht4 serotonin receptor compositions for treating gastrointestinal motility disorders
US20080153832A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Pan-alpha-2 receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
US20080153927A1 (en) * 2006-12-22 2008-06-26 Allergan, Inc. Alpha-2b receptor agonist and relaxant compositions for treating gastrointestinal motility disorders
WO2008104880A2 (en) * 2007-03-01 2008-09-04 Aurobindo Pharma Limited Stable solid dosage forms of an antidepressant
PT1988086E (pt) 2007-04-23 2012-02-28 Synthon Bv Processo para a resolução de citalopram via o seu composto tartarato de citalopram enriquecido em (s)
KR20100028559A (ko) 2007-05-18 2010-03-12 시플라 리미티드 데스메틸시탈로프람을 경유한 에스시탈로프람의 제조방법, 상기 ｓ-이성체의 광학분리 및 메틸화
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
HRP20171908T1 (hr) * 2007-08-03 2018-01-26 Richter Gedeon Nyrt. Farmaceutski pripravak koji sadrži ligande dopamin receptora i metode liječenja koje koriste ligande dopamin receptora
US20090048336A1 (en) * 2007-08-17 2009-02-19 Naveen Kumar Kolla Escitalopram oxalate powders
NZ570884A (en) 2007-09-11 2010-03-26 Lundbeck & Co As H Fractionally crystallising 4-[4-(dimethyl amino)-1-(4'-fluorophenyl)-1-hydroxybutyI]-3-(hydroxymethyl)-benzonitrile and manufacturing escitalopram therefrom
US8022232B2 (en) 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
WO2009111031A2 (en) * 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Methods of treating vasomotor symptoms
CN101538257B (zh) * 2008-03-21 2012-10-17 浙江华海药业股份有限公司 一种制备西酞普兰和s-西酞普兰的方法
CN101265215B (zh) * 2008-04-18 2011-03-16 浙江奥托康制药集团股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
WO2009128057A2 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20110230666A1 (en) * 2008-06-03 2011-09-22 Shodhana Laboratories Limited process for the separation of enantiomerically pure compounds
US20110092719A1 (en) * 2008-06-16 2011-04-21 Shodhana Laboratories Limited Preparation of Escitalopram, Its Salts and Intermediates
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20100249438A1 (en) * 2009-03-30 2010-09-30 Vijaya Bhaskar Bolugoddu Preparation of escitalopram
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
CN102190600B (zh) * 2010-03-13 2015-04-15 浙江华海药业股份有限公司 一种右旋西酞普兰中间体s-型二醇的制备方法
CN102757414B (zh) * 2011-04-25 2014-02-19 齐鲁制药有限公司 艾司西酞普兰草酸盐的制备方法
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
ITMI20120448A1 (it) 2012-01-30 2013-07-31 Carthesia Sas Composizione liofilizzata di escitalopram ossalato per somministrazione sublinguale
ITMI20120105A1 (it) * 2012-01-30 2013-07-31 Carthesia S A S Soluzione acquosa di escitalopram ossalato e relativo utilizzo
CN104119248A (zh) * 2014-08-08 2014-10-29 广东东阳光药业有限公司 S-西酞普兰的制备方法
CN107074750B (zh) * 2014-11-14 2022-03-25 浙江华海药业股份有限公司 一种拆分西酞普兰中间体5-氰二醇的方法
EP3309142B1 (en) 2015-06-09 2020-08-05 Zhejiang Huahai Pharmaceutical Co., Ltd Method for preparing citalopram diol intermediate
CN107311968A (zh) * 2016-03-31 2017-11-03 广州市恒诺康医药科技有限公司 西酞普兰帕莫酸盐和其结晶形态及其制备方法和用途
CN108976188B (zh) * 2017-06-05 2022-12-06 上海奥博生物医药股份有限公司 一种艾司西酞普兰双羟萘酸盐新的制备方法
MX2020003730A (es) 2017-10-09 2020-08-03 Teva Pharma Nueva sal y formas en estado solido de escitalopram.
CN111217777A (zh) * 2018-11-26 2020-06-02 上海奥博生物医药技术有限公司 一种高纯度艾司西酞普兰双羟萘酸盐新的制备工艺
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
KR102441089B1 (ko) 2020-06-15 2022-09-07 환인제약 주식회사 의약 조성물
WO2022153262A1 (en) 2021-01-18 2022-07-21 Anton Frenkel Pharmaceutical dosage form
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method

Also Published As

Publication number Publication date
EP0347066B1 (en) 1995-03-15
IE65734B1 (en) 1995-11-15
DK170280B1 (da) 1995-07-24
CY2007004I1 (el) 2009-11-04
IL90465A (en) 1995-01-24
NL300155I1 (nl) 2004-09-01
ATE119896T1 (de) 1995-04-15
NZ229426A (en) 1990-12-21
AU623144C (en) 1990-01-04
DE68921672D1 (de) 1995-04-20
FI98627C (fi) 1997-07-25
JP3038204B2 (ja) 2000-05-08
NO2002014I2 (no) 2005-03-21
FI892823L (fi) 1989-12-15
FI892823A0 (fi) 1989-06-08
PT90845B (pt) 1994-11-30
ZA894476B (en) 1990-04-25
FI91527B (fi) 1994-03-31
NO172892C (no) 1993-09-22
FI20041359A7 (fi) 2004-10-20
LU90999I2 (fr) 2003-03-17
GB8814057D0 (en) 1988-07-20
HK139596A (en) 1996-08-02
HU211460A9 (en) 1995-11-28
JP3044253B2 (ja) 2000-05-22
JPH11292867A (ja) 1999-10-26
MX9203346A (es) 1992-08-31
ES2068891T3 (es) 1995-05-01
DE68921672T2 (de) 1995-07-27
USRE34712E (en) 1994-08-30
NO892447L (no) 1989-12-15
NL300155I2 (nl) 2005-09-01
DK11593D0 (da) 1993-02-01
DK11593A (da) 1993-02-01
PT90845A (pt) 1989-12-29
FI113762B (fi) 2004-06-15
AU623144B2 (en) 1992-05-07
AU3629589A (en) 1990-01-04
NO172892B (no) 1993-06-14
IE891859L (en) 1989-12-14
DK259989A (da) 1989-12-15
DE10399030I2 (de) 2004-08-12
DK259989D0 (da) 1989-05-29
JPH0236177A (ja) 1990-02-06
FI20041359L (fi) 2004-10-20
EP0347066A1 (en) 1989-12-20
CA1339452C (en) 1997-09-09
CY2007004I2 (el) 2009-11-04
FI20000507L (fi) 2000-03-06
FI941829L (fi) 1994-04-20
FI20000507A7 (fi) 2000-03-06
US4943590A (en) 1990-07-24
CY2081B1 (en) 1998-10-16
ES2068891T4 (es) 2012-02-07
DE10399030I1 (de) 2004-01-08
GR3015889T3 (en) 1995-07-31
FI941829A0 (fi) 1994-04-20
CA1339568C (en) 1997-12-02

Similar Documents

Publication Publication Date Title
NO172892C (no) Fremgangsmaate ved fremstilling av benzofuranderivater
DK89595A (da) Fremgangsmåde til fremstilling af 1-(3-dimethylaminopropyl)-1'-(4-fluorphenyl)-1,3-dihydroisobenzofuran-5-carbonnitril
ATE121066T1 (de) Verfahren zur herstellung von 6,12-dihydro-6- hydroxy-cannabidiol und dessen anwendung zur herstellung von trans-delta-9- tetrahydrocannabinol.
ATE132145T1 (de) Verfahren zur herstellung von bacchatin iii und von desacetyl-10-bacchatin iii derivate
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
DE69018726D1 (de) Cumarinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von zerebrovaskulären Störungen.
ATE116636T1 (de) Verfahren zur herstellung von 2,6- dichlordiphenylaminessigsäurederivaten.
DE69707603D1 (de) Verfahren zur Herstellung von N2-Arylsulfonyl-L-Argininamiden
DE69510787D1 (de) Verfahren zur herstellung von 1-(3-trialkylsilylphenyl)-2,2,2-trifluoromethyl ethanonderivative
ATE131155T1 (de) Verfahren zur herstellung von zwischenprodukten und zur synthese von n-(2-hydroxyethyl)-2- hydroxymethyl-3,4,5-trihydroxypiperidine.
IT8621359A1 (it) Processo per la sintesi di acidi carbossilici
ATE117676T1 (de) Verfahren zur herstellung von molluskiziden 2,4,5-tribrompyrrol-3-carbonitrilen.
ATE188694T1 (de) Verfahren zur herstellung von benzopyranderivaten
DE3575719D1 (de) Imidazoloncarbonylarylimidazole, methode zur herstellung und verwendung sowie wirksame zusammensetzungen davon.
DE69200389D1 (de) Verfahren zur Herstellung von Enantiomeren von 3-Aminchromanderivaten.
ATE159246T1 (de) Verfahren zur herstellung von (s)-vinyl- und (s)- allenyl-gaba
FI875602A0 (fi) Optiskt aktivt tetrahydro-2-furanonderivat saosom miksobicid.
ATE122656T1 (de) Verfahren zur herstellung substituierter indole.
DE3880880D1 (de) 3-(6'-methoxy-2'-naphthylmethyl)-2,4-pentandion, verfahren zur herstellung und zwischenprodukte.

Legal Events

Date Code Title Description
MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2002014

Effective date: 20140613